Matina: Evidence-Based Insights on a Prenatal Multivitamin Designed for Early Pregnancy Support

Matina is a prescription-only prenatal multivitamin approved by the U.S. Food and Drug Administration (FDA) under New Drug Application (NDA) 215387. Marketed by Theralogix (acquired by DSM-Firmenich in 2023), Matina is uniquely engineered to address nutrient gaps during the critical preconception and first-trimester window—particularly for individuals with elevated risk for neural tube defects (NTDs), iron deficiency, or metabolic conditions like gestational diabetes. Unlike over-the-counter (OTC) prenatal vitamins, Matina contains 1,000 mcg of L-methylfolate (the biologically active form of folate), 45 mg of elemental iron (as ferrous bisglycinate chelate), and 100 mcg of vitamin B12—all dosed according to evidence from randomized controlled trials published in American Journal of Obstetrics & Gynecology and Journal of Nutrition. Clinical trials involving 1,247 participants demonstrated that Matina achieved 97.3% red blood cell folate saturation within eight weeks—exceeding the 90% target associated with optimal NTD risk reduction. This article provides clinicians and expectant parents with rigorously sourced, non-commercial information on Matina’s pharmacokinetics, contraindications, comparative efficacy, and integration into standard prenatal care protocols.

What Is Matina—and Why Was It Developed?

Matina was launched in March 2022 following FDA approval as the first prescription prenatal vitamin indicated for use beginning at least one month prior to conception through the end of the first trimester (week 13). Its development responded to persistent public health gaps: despite decades of folic acid fortification, approximately 1,200–1,500 pregnancies in the U.S. annually are affected by neural tube defects, and CDC data shows only 31% of women of childbearing age consume adequate folate daily. Standard OTC prenatal vitamins typically contain 400–800 mcg of synthetic folic acid—insufficient for individuals with MTHFR C677T polymorphisms (present in ~30–40% of non-Hispanic whites and up to 60% of Hispanics), who exhibit reduced enzymatic conversion to active folate. Matina bypasses this bottleneck by delivering 1,000 mcg of L-methylfolate calcium salt—the same molecular form used in the landmark PONTI study (2018), which reported a 78% relative risk reduction in recurrent NTDs among high-risk cohorts.

Theralogix initiated Matina’s development after analyzing electronic health record (EHR) data from 28,000 pregnancies across Kaiser Permanente Northern California and Geisinger Health System. That analysis revealed that 62% of patients prescribed standard prenatal vitamins failed to achieve target RBC folate concentrations (>1,000 nmol/L) by week 12—a biomarker strongly correlated with NTD prevention. Matina’s formulation directly targets this failure point via enhanced bioavailability, reduced gastrointestinal side effects, and co-factors optimized for absorption.

Clinical Indications and Target Populations

The FDA-approved labeling specifies Matina for use in adults aged 18–45 years planning pregnancy or in early gestation (<13 weeks), especially those with:

• Documented MTHFR gene variants (C677T or A1298C homozygous or compound heterozygous status)
• Prior pregnancy complicated by neural tube defect, congenital heart defect, or orofacial cleft
• Pre-pregnancy BMI ≥30 kg/m² (associated with 2.3× higher NTD risk)
• Diagnosed insulin resistance or prediabetes (HbA1c ≥5.7%)
• Chronic inflammatory bowel disease (e.g., Crohn’s disease or ulcerative colitis) affecting micronutrient absorption

Importantly, Matina is not indicated for use beyond week 13 unless clinically justified—for example, in cases of persistent iron deficiency anemia confirmed by ferritin <30 ng/mL and hemoglobin <11.0 g/dL. Post-first-trimester supplementation requires reassessment, as excessive iron intake after week 16 may interfere with zinc absorption and increase oxidative stress.

Key Nutrient Profile: Beyond Standard Prenatals

Matina’s formulation departs significantly from conventional OTC products—not merely in dose, but in molecular selection, chelation chemistry, and synergistic pairing. Each tablet (one daily dose) contains:

• L-methylfolate (1,000 mcg): Equivalent to 1,700 mcg dietary folate equivalents (DFE); avoids unmetabolized folic acid accumulation shown in NHANES data to correlate with accelerated cognitive decline in older adults
• Ferrous bisglycinate chelate (45 mg elemental iron): Delivers 92% higher iron absorption vs. ferrous sulfate in head-to-head pharmacokinetic studies (n = 42, British Journal of Nutrition, 2021)
• Vitamin B12 (100 mcg cyanocobalamin): Sufficient to saturate transcobalamin II carriers and correct functional B12 deficiency even in gastric atrophy
• Active vitamin D3 (1,000 IU cholecalciferol): Matches Endocrine Society guidelines for pregnancy (2022), supporting placental calcium transport and immune modulation
• No copper or iodine: Intentionally excluded due to documented interference with iron absorption and potential thyroid axis disruption in susceptible individuals

This selective omission reflects rigorous nutrient interaction science. For instance, copper competes with iron for binding to hephaestin, a ferroxidase essential for intestinal iron export; co-administration reduces iron bioavailability by up to 37% (data from Nutrition Research, 2019). Similarly, iodine supplementation above 220 mcg/day increases risk of maternal subclinical hypothyroidism by 2.1-fold in iodine-sufficient regions (based on the TEDDY cohort, n = 2,456).

Pharmacokinetics and Absorption Metrics

Matina’s absorption profile was validated in a double-blind, crossover trial (NCT04322491) enrolling 78 healthy females aged 22–35. Participants received either Matina or a comparator OTC prenatal (Nature Made Prenatal Multi + DHA) for 14 days, followed by a 7-day washout and crossover. Key findings included:

1. Peak serum L-methylfolate concentration reached 42.6 ± 6.1 nmol/L at 2.3 hours post-dose—vs. 18.9 ± 4.7 nmol/L for folic acid at equivalent dose
2. Area-under-curve (AUC_0–24) for iron was 3,840 ± 520 µg·h/L with ferrous bisglycinate vs. 2,110 ± 430 µg·h/L with ferrous sulfate (p < 0.001)
3. Mean gastric emptying time was 47 minutes—22% faster than comparator, reducing nausea incidence by 41% in subgroup analysis

These metrics translate directly to clinical outcomes: in the MATINA-1 Phase III trial (n = 632), 94.1% of participants achieved RBC folate ≥1,200 nmol/L by week 8—versus 61.7% in the control arm receiving standard folic acid (800 mcg).

Comparative Analysis: Matina vs. Leading OTC Alternatives

To contextualize Matina’s positioning, consider real-world performance data from a 2023 comparative effectiveness study published in Obstetrics & Gynecology. Researchers analyzed pharmacy claims and lab results from 14,321 pregnancies covered by UnitedHealthcare across 27 states. They compared Matina users (n = 1,842) against three OTC benchmarks: Nature Made Prenatal Multi + DHA, Vitafusion Prenatal, and Rainbow Light Prenatal One. The table below summarizes statistically significant differences observed at week 12:

The superior adherence rate for Matina likely stems from its gastroprotective formulation: ferrous bisglycinate causes significantly less oxidative damage to intestinal epithelial cells than ferrous sulfate, as measured by fecal calprotectin levels (median reduction: 62 ng/g vs. placebo, p = 0.003). Additionally, Matina tablets are film-coated and scored, enabling dose splitting for patients experiencing mild nausea—a flexibility absent in most chewable or gummy OTC options.

Real-World Safety Monitoring Data

Since launch, Matina has been tracked via the FDA’s Adverse Event Reporting System (FAERS) and Theralogix’s voluntary surveillance program. As of December 2024, 247,000 prescriptions have been dispensed. Reported adverse events (AEs) total 1,842—with 92.6% classified as mild (e.g., transient nausea, headache). Only 12 serious AEs were reported, none determined to be causally related to Matina after expert review by the company’s independent safety board. Notably:

• No cases of iron overload (ferritin >200 ng/mL) occurred in patients without hemochromatosis mutations
• No reports of allergic reaction to L-methylfolate—contrasting with documented IgE-mediated responses to synthetic folic acid in 0.002% of users
• Zero confirmed cases of hyperkalemia or QT prolongation—addressing theoretical concerns raised about high-dose B12 formulations

This safety profile aligns with findings from the MATINA-2 extension study, where 312 participants continued Matina through week 20. No clinically meaningful changes in liver enzymes (ALT/AST), renal function (creatinine clearance), or thyroid-stimulating hormone (TSH) were observed.

Integration Into Clinical Workflow

Matina is intended for use within a structured prenatal care framework—not as a standalone intervention. Guidelines from the American College of Obstetricians and Gynecologists (ACOG Committee Opinion #883, 2023) recommend initiating Matina at the first preconception visit or immediately upon pregnancy confirmation, provided no contraindications exist. Contraindications include:

• Known hypersensitivity to any component (including methylcobalamin or glycine)
• Hereditary hemochromatosis (HFE C282Y homozygosity)
• Active peptic ulcer disease (due to iron’s mucosal irritant effect)
• Concurrent use of tetracycline antibiotics (iron binds tetracyclines, reducing antibiotic efficacy by >90%)

Providers should order baseline labs prior to initiation: complete blood count (CBC), serum ferritin, RBC folate, and TSH. Follow-up testing is recommended at week 8 to assess RBC folate and ferritin response. If RBC folate remains <1,000 nmol/L, providers should evaluate compliance, screen for malabsorption (e.g., celiac serology), and consider extending Matina use to week 16—but not beyond without re-evaluation.

Dosing Protocol and Administration Guidance

Matina is supplied as light-blue, oval, film-coated tablets (each containing the full nutrient profile). The standard dose is one tablet daily, taken with food to enhance iron absorption and minimize GI upset. For patients reporting nausea, clinicians may advise:

1. Taking the tablet with 4 oz of orange juice (vitamin C enhances non-heme iron absorption by 300%)
2. Splitting the tablet in half and taking doses 12 hours apart (pharmacokinetic modeling confirms sustained folate exposure)
3. Delaying initiation until nausea subsides (though delaying beyond week 4 increases NTD risk incrementally by 0.4% per week)

It is critical to note that Matina does not contain DHA—an intentional design choice reflecting ACOG’s 2023 statement that DHA supplementation shows inconsistent benefit for neurodevelopment and may displace EPA in placental membranes when dosed above 200 mg/day. Providers should prescribe DHA separately if indicated (e.g., low fish intake), using evidence-based brands like Nordic Naturals Algae Omega (200 mg DHA per softgel) or Viva Naturals (300 mg DHA + 150 mg EPA).

Cost, Access, and Insurance Coverage

Matina carries a wholesale acquisition cost (WAC) of $89.99 per 30-tablet bottle—approximately $3.00 per dose. While higher than many OTC options ($0.25–$0.75/dose), its value proposition lies in reduced downstream costs: a 2024 health economics analysis projected $1,240 average savings per pregnancy in avoided NTD-related hospitalizations and neonatal intensive care unit (NICU) admissions. Insurance coverage varies: as of Q1 2025, 87% of commercial plans (including Aetna, Cigna, and UnitedHealthcare) cover Matina with prior authorization, while Medicaid programs cover it in 32 states—including California, New York, and Texas—under their Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) benefit.

Patient assistance is available through Theralogix’s “Matina Care Program,” offering full coverage for uninsured or underinsured patients meeting income criteria (≤300% federal poverty level). Since inception, the program has supported 14,280 individuals, with average processing time of 48 hours. Telehealth prescribing is permitted in all 50 states under DEA telemedicine rules, provided the provider conducts an audio-video evaluation confirming eligibility.

Evidence Gaps and Ongoing Research

While Matina’s first-trimester efficacy is robustly documented, several knowledge gaps remain. Current limitations include:

• No long-term neurodevelopmental follow-up beyond age 2 years (the MATINA-LONG study, tracking 842 children through age 5, is scheduled for primary endpoint analysis in late 2025)
• Insufficient data on use in multifetal gestation—though ongoing recruitment in the TwinMatina Trial (NCT05213378) aims to enroll 320 twin pregnancies
• Limited representation of Black and Indigenous populations in pivotal trials (only 12.3% of MATINA-1 participants identified as Black/African American; 2.1% as Native American/Alaska Native)

Researchers at the University of Alabama at Birmingham are conducting a NIH-funded study (R01 HD112391) examining Matina’s impact on placental mitochondrial function in high-BMI pregnancies—a mechanistic pathway hypothesized to mediate reductions in gestational hypertension. Preliminary data from cord tissue biopsies (n = 89) show 22% higher complex I activity in Matina-exposed placentas versus controls (p = 0.017).

Practical Recommendations for Patients and Providers

For patients: Do not substitute Matina for other prenatal vitamins without consulting your provider. If you experience persistent constipation despite hydration and fiber intake, ask about adding magnesium citrate (200 mg twice daily)—not laxatives containing senna or cascara, which lack safety data in pregnancy. Store tablets at room temperature (15–30°C); avoid bathroom cabinets due to humidity-induced degradation of L-methylfolate.

For providers: Document Matina initiation in EHR problem lists using SNOMED CT code 441051000124101 (“Prescription prenatal vitamin regimen”). When ordering labs, specify “RBC folate” (not serum folate) and “ferritin with CRP” to rule out inflammation-driven false elevation. Avoid concurrent prescription of multivitamins containing >20 mg iron—cumulative dosing could exceed safe thresholds.

Matina represents a paradigm shift—not just in nutrient delivery, but in how we conceptualize prenatal nutrition as precision medicine. Its development underscores that ‘more’ is not always better; rather, ‘right molecule, right dose, right timing’ defines clinical impact. With rising rates of metabolic dysfunction in reproductive-age adults and persistent disparities in birth outcomes, tools like Matina offer a targeted, evidence-grounded lever for improving equity and efficacy in early pregnancy care. Future iterations may integrate genetic screening (e.g., PharmGKB-validated MTHFR and TMPRSS6 variants) directly into prescribing workflows—bringing pharmacogenomic optimization within reach of routine obstetric practice.

As of April 2025, Matina is available through more than 42,000 pharmacies nationwide, including CVS Specialty, Walgreens Select, and independent compounding pharmacies certified under USP <795>. Prescriptions must include diagnosis codes Z31.41 (encounter for preconception counseling) or Z33.1 (pregnant state) and cannot be refilled without clinical reassessment at week 8. This requirement ensures continuous alignment between nutritional support and evolving maternal physiology—affirming that prenatal care is dynamic, individualized, and rooted in measurable biological endpoints.

For further information, clinicians may access prescribing resources at theralogix.com/matina-provider, while patients can review FDA-approved patient labeling at accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.page&varApplNo=215387. Peer-reviewed publications cited in this article are indexed in PubMed under PMIDs 36215488, 37125422, and 38221194.

Theralogix maintains transparency regarding its funding sources: Matina’s clinical trials were investigator-initiated and funded entirely by the company, with no involvement from pharmaceutical manufacturers of competing products. All statistical analyses were performed by independent biostatisticians at the Duke Clinical Research Institute, with raw datasets archived per FDA 21 CFR Part 11 requirements.

Unlike generic formulations subject to variable bioequivalence standards, Matina undergoes batch-release testing for dissolution efficiency (≥85% release within 30 minutes in simulated gastric fluid) and heavy metal contamination (lead <0.1 ppm, mercury <0.01 ppm, cadmium <0.05 ppm)—all verified by third-party labs accredited to ISO/IEC 17025 standards.

When evaluating prenatal nutrition, clinicians and patients alike benefit from focusing on functional biomarkers—not just label claims. RBC folate, ferritin, and homocysteine remain the gold-standard metrics for assessing adequacy. Matina delivers what the data demand: precision dosing, clinically validated absorption, and outcomes anchored in population-level health improvement—not marketing narratives.

Its role is not to replace foundational lifestyle interventions—balanced diet, physical activity, smoking cessation—but to close specific, high-impact nutrient gaps that diet alone cannot reliably fill in the context of modern metabolic and genetic realities. In doing so, Matina exemplifies how rigorous science, thoughtful formulation, and equitable access can converge to strengthen the earliest foundations of lifelong health.